Treatment of endometriosis of uterosacral ligament and rectum through the vagina: description of a modified technique

Camara, O.; Herrmann, Jens; Egbe, A; Kavallaris, Andreas; Diebolder, Herbert; Gajda, Mieczysław; Runnebaum, Ingo B.

doi:10.1093/humrep/dep016

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disease can be asymptomatic or appear with nausea, chronic pelvic pain, constipation, diarrhea, pain during defecation, hemorrhage. Signs of bowel obstruction or perforation can be observed [1][2][3][4][5][6][7][8]. Not often, bleeding within the lesions can cause hemoperitoneum and acute abdominal pain.…”

Section: Discussionmentioning

confidence: 99%

Rectal endometriosis: a case report

et al. 2011

View full text Add to dashboard Cite

We present the case of a 45-year-old female patient who was admitted with a history of pelvic pain, constipation, and dysmenorrhea. CT scan and u/s images revealed cholelithiasis, benign nodular hyperplasia of segment IV of the liver and uterine fibromyoma. During laparotomy, firm adhesions between the posterior wall of the uterus and the rectum were found and the incisional biopsy reveals an undifferentiated adenocarcinoma. Then, total resection of the uterus was performed with en block resection of the adherent part of the rectum and part of the posterior wall of the vagina. The final histopathological report showed the presence of uterine fibromyoma, nodular hyperplasia of the liver and rectal endometriosis without any sign of malignancy. The patient after 5 years of follow up remains healthy. Rectal endometriosis represents an uncommon localization of pelvic endometriosis where the symptoms and clinical findings are non-specific making the definitive preoperative diagnosis difficult. Endometriosis should be included in the differential diagnosis of chronic pelvic pain in combination with defecation disorders in female patients of reproductive age.

show abstract

Section: Discussionmentioning

confidence: 99%

Rectal endometriosis: a case report

et al. 2011

View full text Add to dashboard Cite

show abstract

“…While it is asymptomatic in some women, endometriosis is often associated with dysmenorrhea, dyspareunia, pelvic pain, and infertility 1 . Pain is the most debilitating complaint since it has a negative impact on sexual function, social activity, ability to work, and overall well‐being and quality of life 1‐3 . Endometriosis occurs in 5‐10% of women of reproductive age, with a peak prevalence between the ages of 25 and 35 years 1‐4 .…”

Section: Introductionmentioning

confidence: 99%

“…Pain is the most debilitating complaint since it has a negative impact on sexual function, social activity, ability to work, and overall well‐being and quality of life 1‐3 . Endometriosis occurs in 5‐10% of women of reproductive age, with a peak prevalence between the ages of 25 and 35 years 1‐4 . Pharmacological therapies play a pivotal role in the long‐term management of ovarian endometriomas to control pain, and usually involve hormonal treatments aimed at suppressing ovarian function.…”

Section: Introductionmentioning

confidence: 99%

“…5-10% of women of reproductive age, with a peak prevalence between the ages of 25 and 35 years. [1][2][3][4] Pharmacological therapies play a pivotal role in the long-term management of ovarian endometriomas to control pain, and usually involve hormonal treatments aimed at suppressing ovarian function. These include combination oral contraceptives, danazol, gonadotropin-releasing hormone (GnRH) agonists, and progestogens.…”

mentioning

confidence: 99%

“…1 Pain is the most debilitating complaint since it has a negative impact on sexual function, social activity, ability to work, and overall well-being and quality of life. [1][2][3] Endometriosis occurs in…”

mentioning

confidence: 99%

See 2 more Smart Citations

An assessment of the efficacy and safety of dydrogesterone in women with ovarian endometrioma: An open‐label multicenter clinical study

Kitawaki

Koga

Kanzo³

et al. 2021

Reprod Medicine & Biology

View full text Add to dashboard Cite

Purpose To assess the efficacy and safety of dydrogesterone in Japanese women with ovarian endometrioma in a real‐world setting. Methods The post‐marketing study involved 15 sites in Japan. Dydrogesterone 10 mg twice daily orally was administered for 21 days (day 5‐25 of each menstrual cycle) for 4 cycles. The primary outcome measure was the change in ovarian endometrioma volume from baseline. Secondary outcome measures included total dysmenorrhea score (0 = absent to 3 = severe), severity of dysmenorrhea pain [0‐10cm visual analog scale (VAS)], serum carbohydrate antigen 125 (CA‐125) levels, and safety. Results The study group comprised women with an endometrioma aged 20 to 49 (47.4% cases aged ≥40 years). Endometrioma volume was reduced in 50% (26/52), unchanged in 25% (13/52), and increased in 25% (13/52) of women from baseline to the end of cycle 5; three‐quarters of patients thus had either reduced or unchanged ovarian endometrioma volume. Dydrogesterone significantly reduced total dysmenorrhea scores and severity of dysmenorrhea pain VAS during treatment compared with baseline. CA‐125 levels were not significantly changed during the study. The incidence of adverse events and adverse drug reactions in 59 subjects was 13.6% and 11.9%. Conclusions Dydrogesterone prevented an increase in endometrioma size in many women, and it also significantly improved total dysmenorrhea scores and severity of dysmenorrhea pain, and was well tolerated. The ClinicalTrials.gov identifier of the study was NCT02921763.

show abstract